Equity performance in January dictates the year

<p>Equity performance in January dictates the year, or so goes the old stock market adage. Following positive employment, retail, and housing data from the world’s […]</p>

  • Equity performance in January dictates the year, or so goes the old stock market adage. Following positive employment, retail, and housing data from the world’s largest economy, global stock markets ended the first week of 2012 in the blue. The Dow Jones was up 1.2%, the DAX was up 2.46% and here in London, the FTSE 100 closed up 1.3%.

    Volume decreased as the week progressed though. 6.3 billion shares were dealt on the NYSE on Friday, which is nearly 25% less than the daily average for 2011. Market participants were cautious as European indices hit 2-month highs ahead of a busy calendar for week 2 of 2012.

    Today, the FTSE 100 is trading at 5650 at 10am and is flat on the day. Trading up 2.4% to 624p, Arm Holdings is the top gainer so far Monday. Citigroup has upgraded the company and increased its share price target to 700p from 600p. Following the release of clinical trial results, GlaxoSmithkline has announced it will file for regulatory approval for once-a-day inhaled lung drug Relovair. The stock is trading down 2.8% to 1455p and is the largest faller on the FTSE 100. Whilst warranting selling commercially, the trial data suggests the drug is not superior to GSK’s existing respiratory drug, Advair.

    The performance of the euro last week was in direct contrast to equity markets as the currency hit 16-month lows against the US dollar and 11-year lows against the Japanese yen. FX traders, keen to hear more on the plans for eurozone fiscal discipline can tune in to a joint conference from the leaders of Europe’s two largest economies.  “Merkozy” will be speaking at 1.30pm today. Also weighing on the minds of currency speculators this week are the latest attempts by two of the continent’s financially troubled countries to raise funds. Thursday and Friday bring the latest round of Bond Auctions from Spain and Italy respectively. A low take up of the allocation could see a further sell off for the euro.  The euro is, however, trading up 86 points against the USD this morning at 1.2780.

    Worries over possible supply disruptions for crude oil saw NYMEX crude jump 2.8% last week ($101.56 a barrel). Talks are ongoing over more sanctions for Iran following their announcement of new military exercises in the crucial Strait of Hormuz. Oil traders will need to keep a close eye on this story and on escalating events in Nigeria, as strikes and production outages impact on supply there.

    Q4 earnings season begins today
    In equities, Alcoa today and JP Morgan on Friday are the headliners as the first week of the US fourth quarter earnings season begins today. A positive season could lift the stock market above current overhead resistance.

    In London this week it is a busy schedule for retailers, recruiters and homebuilders as no less than 12 companies in the three sectors make announcements. Of particular interest is how the retailers and supermarkets have fared over the crucial Christmas trading period. Tesco, Sainsbury and Marks & Spencer are the highlights, but a full diary can be found in the companies reporting page.

  • From time to time, City Index Limited’s (“we”, “our”) website may contain links to other sites and/or resources provided by third parties.  These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content.  Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell.  You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure.  No representation or warranty is made, express or implied, that the materials on our website are complete or accurate.  We are not under any obligation to update any such material.

    As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website and any such liability is hereby expressly disclaimed.

Build your confidence risk free
Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.